Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease
{{output}}
Objectives: Infliximab (IFX) is highly effective but costly, driving the adoption of biosimilars. Data on switching from originator IFX to biosimilars in pediatric inflammatory bowel disease (IBD) patients remain limited. This st... ...
